Article
Biochemistry & Molecular Biology
Paolo Previtali, Lisa Pagani, Giulia Risca, Giulia Capitoli, Eleonora Bossi, Glenda Oliveira, Isabella Piga, Antonella Radice, Barbara Trezzi, Renato Alberto Sinico, Fulvio Magni, Clizia Chinello
Summary: Proteomic analysis reveals that the abnormal expression of specific proteins may be associated with idiopathic membranous nephropathy (IMN) and nephrotic syndrome (NS), but not with other glomerulopathies in nondiabetic adults. IMN may be related to dysregulation of lipid metabolism, activation of non-classical complement pathways, and involvement of ficolin-2. Additionally, mannose receptor CD206 and biotinidase could serve as reliable markers to distinguish IMN from other glomerulopathies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Urology & Nephrology
Shane A. Bobart, Heedeok Han, Shahrzad Tehranian, An S. De Vriese, Juan Carlos Leon Roman, Sanjeev Sethi, Ladan Zand, Cristina Andrades Gomez, Callen D. Giesen, Maria Jose Soler, Andrew S. Bomback, Fernando C. Fervenza
Summary: The study aimed to investigate whether a positive anti-phospholipase A2 receptor antibody test through immunological testing can confirm the diagnosis of membranous nephropathy without the need for kidney biopsy. The results showed that in certain specific conditions, a positive antibody test can effectively diagnose membranous nephropathy.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Urology & Nephrology
Rebecca I. Spain, Nicole K. Andeen, Pamela C. Gibson, Mary H. Samuels, Cynthia D. Morris, Andrew J. Solomon, Richard Solomon, Carin Waslo, Rupali S. Avasare
Summary: Lipoic acid, a popular antioxidant and insulin-mimetic supplement, was found to cause high-grade proteinuria in multiple sclerosis patients in a clinical trial. This led to the discovery of NELL1-associated membranous nephropathy cases related to lipoic acid supplementation, which improved with discontinuation of the supplement and supportive therapy.
KIDNEY INTERNATIONAL
(2021)
Review
Medicine, General & Internal
Su Woong Jung, Ju-Young Moon
Summary: Treatment of diabetic kidney disease faces unmet needs due to its complex pathophysiology and difficulty in treatment translation, requiring improved diagnostic tools to better distinguish subgroups. Chronic disease has not seen significant improvement in treatment.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2021)
Review
Medicine, General & Internal
Pierre Ronco, Laurence Beck, Hanna Debiec, Fernando C. Fervenza, Fan Fan Hou, Vivekanand Jha, Sanjeev Sethi, Allison Tong, Marina Vivarelli, Jack Wetzels
Summary: Membranous nephropathy (MN) is a glomerular disease that can occur at any age, with about 80% of adult patients having no apparent cause. It is an autoimmune disease with unpredictable disease outcome, with some patients experiencing spontaneous remission. Various treatment options are available, but relapses and suboptimal treatment responses remain a challenge.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Article
Endocrinology & Metabolism
Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Summary: This study examined the changes in diabetic kidney disease (DKD) phenotypes over a 2-year period and found that these changes were associated with the risk of hospitalization for heart failure (HHF). The presence of proteinuria (PU) was particularly predictive of HHF risk.
DIABETES & METABOLISM JOURNAL
(2023)
Article
Endocrinology & Metabolism
Hua-Xing Huang, Liang-Lan Shen, Hai-Yan Huang, Li-Hua Zhao, Feng Xu, Dong-Mei Zhang, Xiu-Lin Zhang, Tong Chen, Xue-Qin Wang, Yan Xie, Jian-Bin Su
Summary: The study revealed that both fasting and postchallenge glucagon levels were independently associated with DKD in patients with type 2 diabetes mellitus. Patients with higher glucagon levels were at increased risk of developing DKD, highlighting the importance of monitoring glucagon levels in T2DM patients.
DIABETES & METABOLISM JOURNAL
(2021)
Article
Urology & Nephrology
Chatchai Kreepala, Pitirat Panpruang, Rapeeporn Yodprom, Teeraya Piyajarawong, Krittanont Wattanavaekin, Taechasit Danjittrong, Sadiporn Phuthomdee
Summary: FRMD3 gene polymorphisms may be used as an alternative test to differentiate diabetic nephropathy (DN) from nondiabetic renal disease (NDRD) in type 2 diabetes mellitus (DM) patients. The C allele, especially homozygous CC, was associated with NDRD pathology in patients with overt proteinuria.
KIDNEY RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Urology & Nephrology
Yann Salemkour, Dilemin Yildiz, Lea Dionet, Daan C. 't Hart, Kim A. T. Verheijden, Ryuta Sato, Nassim Mahtal, Jean-Daniel Delbet, Emmanuel Letavernier, Marion Rabant, Alexandre Karras, Johan van der Vlag, Tom Nijenhuis, Pierre-Louis Tharaux, Olivia Lenoir
Summary: This study reveals a new mechanism linking TRPC6 and calpain activity to impaired podocyte autophagy, podocyte injury, and proteinuria in diabetic kidney disease. Targeting TRPC6 and/or calpain to restore podocyte autophagy may offer a promising therapeutic strategy for diabetic kidney disease.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Endocrinology & Metabolism
Alice Giontella, Loukas Zagkos, Milan Geybels, Susanna C. Larsson, Ioanna Tzoulaki, Christos S. Mantzoros, Birgitte Andersen, Dipender Gill, Helene T. Cronje
Summary: This study investigates the effects of fibroblast growth factor 21 (FGF21) on kidney function using a genetic variant as an instrumental variable. The results suggest that genetically predicted FGF21 has renoprotective effects and is associated with lower risk of chronic kidney disease (CKD) and improved cardiometabolic profiles. This highlights the potential repurposing opportunity of FGF21 for the treatment and prevention of kidney disease.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2023)
Article
Endocrinology & Metabolism
Shunlai Shang, Shaoyuan Cui, Wenjuan Wang, Chao Wang, Ping Li, Wenge Li, Qinggang Li
Summary: This study analyzed the safety and efficacy of leflunomide combined with low-dose methylprednisolone in the treatment of diabetic kidney disease combined with membranous nephropathy. The combination therapy was found to be more effective than leflunomide monotherapy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Chemistry, Medicinal
Hao Li, Wenni Dai, Zhiwen Liu, Liyu He
Summary: Diabetic kidney disease is a major cause of end-stage kidney disease worldwide, and new drug delivery strategies and targeted therapies are urgently needed.
Review
Urology & Nephrology
Sayako Maruno, Tetsuhiro Tanaka, Masaomi Nangaku
Summary: Diabetic kidney disease is a major challenge and the leading cause of end-stage kidney disease. Although the exact mechanism is not completely understood, several factors including hyperfiltration, oxidative stress, inflammation, hypoxia, and epigenetics are associated with its progression. Studies have shown that sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and mineralocorticoid receptor antagonists have renoprotective effects, while other potential therapeutic candidates are being explored. New targets, such as oxidative stress and inflammation pathways, are of great interest, and various drugs are under investigation. The discovery of new therapeutic options could provide alternative treatments for diabetic kidney disease.
KIDNEY RESEARCH AND CLINICAL PRACTICE
(2022)
Article
Urology & Nephrology
Sumaiya Ahmed, David Massicotte-Azarniouch, Mark Canney, Clare Booth, Paula Blanco, Gregory L. Hundemer
Summary: This case report describes the clinical course of a patient with membranous nephropathy who developed post-infectious glomerulonephritis during the observation period. The patient experienced a rapid decline in kidney function, but responded well to immunosuppressive therapy.
Review
Immunology
Benjamin Y. F. So, Gary C. W. Chan, Desmond Y. H. Yap, Tak Mao Chan
Summary: Primary membranous nephropathy (MN) is a significant cause of nephrotic syndrome and chronic kidney disease (CKD) in adults. The complement system plays a crucial role in the pathogenesis of MN, and detection of complement activation products could serve as a promising tool for non-invasive disease monitoring and prognosis. However, further research is needed to address concerns regarding the risk of infection and high treatment costs associated with complement-directed therapies.
FRONTIERS IN IMMUNOLOGY
(2022)